Supplemental Table 1. CAR-T cells products’ characteristics

|                                | Total (n = 44) | CD3\text{LOW} (n = 20) | CD3\text{HIGH} (n = 24) | P    |
|--------------------------------|---------------|-------------------------|--------------------------|------|
| Transduction efficiency by CAR qPCR (copies/cell) |               |                         |                          | 0.020|
| Median (range)                 | 0.47 (0.14–1.08) | 0.42 (0.2–0.99)          | 0.57 (0.14–1.08)          |      |
| Viable T cells (%)             |               |                         |                          | 0.433|
| Median (range)                 | 99.5 (98.3–99.9) | 99.6 (98.8–99.9)         | 99.5 (98.3–99.7)          |      |
| CAR expression by flow cytometry (%) |               |                         |                          | 0.085|
| Median (range)                 | 23.2 (7.8–41.4) | 21.1 (11.2–36.0)         | 25.9 (7.8–41.4)           |      |
| Release of IFN\text{γ} in response to CD19 expressing target cells (fg/transduced cell) |               |                         |                          | 0.724|
| Median (range)                 | 80 (16–388)   | 80 (37–346)             | 78 (16–388)               |      |
| Infused CAR-T cell number (10\text{⁸}) |               |                         |                          | 0.390|
| Median (range)                 | 6.67 (0.71–12.5) | 7.41 (0.71–12.5)        | 5.84 (0.82–12.1)          |      |

Abbreviations: CAR, chimeric antigen receptor; IFN, interferon
Supplementary Table 2. CRS characteristics according to the number of CD3⁺ cells at leukapheresis.

|                  | Total (n = 44) | CD3́LOW (n = 20) | CD3́HIGH (n = 24) | P      |
|------------------|----------------|-------------------|-------------------|--------|
| CRS              |                |                   |                   | 1.000  |
| Yes              | 41 (93.2)      | 19 (95.0)         | 22 (91.7)         |        |
| No               | 3 (6.8)        | 1 (5.0)           | 2 (8.3)           |        |
| CRS grade        |                |                   |                   | 0.366  |
| 1                | 32 (78.0)      | 13 (68.4)         | 19 (86.4)         |        |
| 2                | 7 (17.1)       | 5 (26.3)          | 2 (9.1)           |        |
| 3                | 2 (4.9)        | 1 (5.3)           | 1 (4.5)           |        |
| Tocilizumab admin|                |                   |                   | 1.000  |
| Yes              | 27 (61.4)      | 12 (60.0)         | 15 (62.5)         |        |
| No               | 17 (38.6)      | 8 (40.0)          | 9 (37.5)          |        |

Abbreviations: CRS, cytokine release syndrome
Supplementary Table 3. Disease status at apheresis and CAR-T infusion, and post-apheresis and lymphocyte depletion therapy according to the number of CD3$^+$ cells at leukapheresis.

| Disease status at apheresis | Total (n = 44) | CD3$^\text{LOW}$ (n = 20) | CD3$^\text{HIGH}$ (n = 24) | P |
|-----------------------------|---------------|----------------------------|----------------------------|---|
| CR                          | 1 (2.3)       | 0 (0.0)                    | 1 (4.2)                    | 0.697 |
| PR                          | 13 (29.5)     | 5 (25.0)                   | 8 (33.3)                   |     |
| SD                          | 20 (45.5)     | 11 (55.0)                  | 9 (37.5)                   |     |
| PD                          | 10 (22.7)     | 4 (20.0)                   | 6 (25.0)                   |     |
| Bridging chemotherapy       |               |                            |                            | 0.966 |
| Gem based chemotherapy      | 16 (36.4)     | 7 (35.0)                   | 9 (37.5)                   |     |
| Other intensive chemotherapy| 18 (40.9)     | 9 (45.0)                   | 9 (37.5)                   |     |
| Reduced intensity therapy   | 3 (6.8)       | 1 (5.0)                    | 2 (8.3)                    |     |
| No                          | 7 (15.9)      | 3 (15.0)                   | 4 (16.7)                   |     |
| Lymphocyte depletion chemotherapy | 0.356 |
| FluCy                       | 37 (84.1)     | 18 (90.0)                  | 19 (79.2)                  |     |
| Bendamustine based          | 5 (11.4)      | 1 (5.0)                    | 4 (16.7)                   |     |
| Others                      | 1 (2.3)       | 1 (5.0)                    | 0 (0.0)                    |     |
| No                          | 1 (2.3)       | 0 (0.0)                    | 1 (4.2)                    |     |
| Disease status at infusion  |               |                            |                            | 0.217 |
| CR                          | 4 (9.1)       | 0 (0.0)                    | 4 (16.7)                   |     |
| PR                          | 11 (25.0)     | 4 (20.0)                   | 7 (29.2)                   |     |
| SD                          | 12 (27.3)     | 7 (35.0)                   | 5 (20.8)                   |     |
| PD                          | 17 (38.1)     | 9 (45.0)                   | 8 (33.3)                   |     |

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; Gem, Gemcitabine; FluCy, Fludarabine and Cyclophosphamide.
Supplementary Table 4. Blood count after CAR-T cell infusion according to the number of CD3$^+$ cells at leukapheresis (median, range).

|            | Total (n = 44) | CD3$^{\text{LOW}}$ (n = 20) | CD3$^{\text{HIGH}}$ (n = 24) | P       |
|------------|----------------|-----------------------------|-----------------------------|---------|
| **WBC (10$^9$/L)** |                |                             |                             |         |
| Day 0      | 1.72 (0.07-7.43) | 1.42 (0.07-5.57)            | 1.84 (0.33-7.43)            | 0.444   |
| Day 7      | 1.94 (0.15-16.06) | 1.42 (0.15-7.97)            | 2.36 (0.36-16.06)           | 0.115   |
| Day 14     | 2.16 (0.62-6.62)  | 2.16 (0.62-6.62)            | 2.19 (0.60-6.18)            | 0.929   |
| **Hb (g/dL)** |                |                             |                             |         |
| Day 0      | 8.65 (6.70-12.70) | 8.55 (6.70-12.70)           | 9.65 (6.70-12.50)           | 0.345   |
| Day 7      | 8.50 (6.50-11.40) | 8.10 (7.10-10.90)           | 8.65 (6.50-11.40)           | 0.155   |
| Day 14     | 9.35 (6.20-12.20) | 8.95 (6.20-12.20)           | 9.70 (6.50-12.10)           | 0.098   |
| **Plt (10$^9$/L)** |            |                             |                             |         |
| Day 0      | 124.00 (7.00-327.00) | 118.50 (7.00-265.00)        | 132.00 (18.00-327.00)       | 0.786   |
| Day 7      | 99.00 (16.00-249.00) | 99.00 (16.00-226.00)        | 101.50 (33.00-249.00)       | 0.990   |
| Day 14     | 107.50 (23.00-406.00) | 106.00 (23.00-406.00)       | 121.00 (25.00-279.00)       | 0.741   |

Abbreviations: WBC, white blood cell; Hb, hemoglobin; Plt, platelet.